to treat and/or prevent neuropathic pain in a subject; or

to treat and/or prevent movement disorders in a subject.

9. ~~A method~~Use of a CNS-active compound of one of claims 1-4 for the manufacture of a medicament for modulating CNS activity~~. the method comprising: administering a CNS-active compound of one of claims 1-4 to a subject~~.

10. ~~A method~~The use as in claim 9, wherein the CNS-active compound is combined with a pharmaceutically-acceptable carrier.

11. ~~A method~~The use as in claim 9, wherein the CNS-active compound is to be administered to the subject in a therapeutically effective amount to modulate CNS activity in the subject.

12. ~~A method~~The use as in claim 11, wherein the therapeutically effective amount is sufficient for at least one of the following:

to provide anticonvulsant activity to a subject;

to treat and/or prevent convulsions in a subject;

to treat and/or prevent seizures in a subject;

to treat and/or prevent spasticity in a subject;

to treat and/or prevent affective mood disorders in a subject;

to treat and/or prevent bipolar mood disorder in a subject;

to treat and/or prevent chronic headaches in a subject;

to treat and/or prevent cluster headaches in a subject;

to treat and/or prevent migraine headaches in a subject;

to treat and/or prevent restlessness syndromes in a subject;


to treat and/or prevent neuropathic pain in a subject: or

to treat and/or prevent movement disorders in a subject.

13. ~~A method~~The use as in claim 11, wherein the therapeutically effective amount is sufficient to treat and/or prevent the symptoms of at least one of anxiety, depression, insomnia, migraine headaches, schizophrenia, Parkinson's disease, spasticity, Alzheimer's disease, bipolar disorder, chronic or neuropathic pain, stroke, chronic neurodegenerative diseases, Huntington's disease, traumatic brain injury, spinal cord injury, or *status epilepticus*.

14. ~~A method~~The use as in claim 11, wherein the therapeutically effective amount is sufficient for a chemical countermeasure.

15. A method of manufacturing a CNS-active compound [3-(4-cyanophenoxy)butyramide], the method comprising:



16. A method as in claim 15, further comprising:

heating 4-cyanophenol in a basic solution at reflux;

adding β-butyrolactone to the refluxing solution;

cooling the solution to room temperature:

preparing a biphasic mixture of the solution by adding water and diethyl ether;

removing a diethyl ether layer after formation;

acidifying the aqueous layer after formation by adding a HCl solution at about *p*H~2;

extracting the acidified aqueous layer with ethyl acetate;

drying the ethyl acetate layer to yield 3-(4-cyanophenoxy)butyric acid];

preparing a solution of 3-(4-cyanophenoxy)butyric acid in an organic solvent;